Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
Background. Management of multiple-endocrine neoplasia type 1- (MEN1-) associated hyperparathyroidism is associated with high recurrence rates and high surgical morbidity due to multiple neck explorations. Cinacalcet, a calcimimetic agent licensed for the treatment of secondary hyperparathyroidism a...
Saved in:
Main Authors: | V. J. Moyes, J. P. Monson, S. L. Chew, S. A. Akker |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2010/906163 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cinacalcet Treatment of Primary Hyperparathyroidism
by: H. M. Rothe, et al.
Published: (2011-01-01) -
Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation
by: Habib Mawad, et al.
Published: (2017-01-01) -
Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy
by: Piergiorgio Bolasco, et al.
Published: (2010-01-01) -
Hereditary vitamin D resistant rickets (HVDRR) case series: phenotype,
genotype, conventional treatment, and adjunctive cinacalcet therapy
by: Noman Ahmad, et al.
Published: (2024-05-01) -
Spontaneous Resolution of Primary Hyperparathyroidism in Parathyroid Adenoma
by: Sara J. Micale, et al.
Published: (2012-01-01)